insights_auto
Why is AXGN down 2,87%?
Dive Deeperchevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
56,95 $
arrow_downward
-2,87%(-1,68) 1D
12 қар., 09:38:27 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
57,75 $
High
58,30 $
Low
55,17 $
Mkt. cap
3,40 млрд
Avg. vol.
1,93 млн
Volume
2,71 мың
52-wk high
58,30 $
52-wk low
23,00 $
EPS
-0,68 $
Beta
1,21
Shares outstanding
59,73 млн
No. of employees
622
Open
57,75 $
High
58,30 $
Low
55,17 $
Mkt. cap
3,40 млрд
Avg. vol.
1,93 млн
Volume
2,71 мың
52-wk high
58,30 $
52-wk low
23,00 $
EPS
-0,68 $
Beta
1,21
Shares outstanding
59,73 млн
No. of employees
622
News stories
From web sources and news partners
Yahoo Finance Singapore
·
7 сағат бұрын
Axogen (AXGN) Stock Could Be 22% Overvalued On Cash Flow Expectations
Investing.com
·
20 сағат бұрын
Axogen stock hits 52-week high at $52.92
Investing.com
·
22 сағат бұрын
AxoGen at Canaccord forum: growth plan widens beyond nerve repair
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Флорида, Америка Құрама Штаттары
SectorHealth Care
IndustryMedical device
Websiteaxogeninc.com